Cystic Fibrosis: Utilizing Personalized Treatments and Addressing Health Disparities
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Guidelines are available to assist health care professionals (HCPs) and caregivers in evaluating and monitoring individuals, detecting complications and preventing clinical deterioration. Despite this, disparities are found in the management and outcome of individuals with CF. It is plausible that these disparities in disease outcome result from delayed diagnosis, lack of specialized care and limited access to medications. In CF, there are multiple gravity phenotypes and clinical manifestations that are described and come from complex interactions between mutations in the CFTR gene, modifier genes, environment and lifestyle. Thus, personalized medicine is essential in CF management.
During this activity, presenters will discuss CF and the different genetic etiologies and examine how an individual’s genetic profile can be utilized to develop a personalized treatment plan. The role that an informed interprofessional health care team can play in improved disease outcomes will also be examined.
This activity is provided by OptumHealth Education and UnitedHealthcare.
No commercial support was received for this activity.
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
This activity is designed to meet the educational needs of case managers, counselors, nurses, nurse practitioners, pharmacists, pharmacy technicians, PAs, physicians, psychologists, social workers, therapists and other HCPs who treat individuals with CF.
At the end of this educational activity, participants should be able to:
- Describe CF and its different genetic etiologies.
- Explain how an individual’s genetic profile can be utilized to develop a personalized CF treatment plan.
- Discuss the prevalence of CF in different racial and ethnic groups.
- Address health disparities among individuals with CF related to their socioeconomic status, residential geographic location and access to genetic evaluations and CF centers.
- Recognize other environmental factors that impact outcomes for individuals with CF.
Peter J. Mogayzel, Jr, MD, PhD, MBA
Menowitz/Rosenstein Professor of Pediatric Respiratory Sciences
Johns Hopkins University School of Medicine
Director, Eudowood Division of Pediatric Respiratory Sciences
Director, Cystic Fibrosis Center
Johns Hopkins Hospital
Dr. Peter Mogayzel is the Menowitz/Rosenstein Professor of Pediatric Respiratory Sciences at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pediatric pulmonary medicine and the treatment of CF. He has served as the Director of the Johns Hopkins Cystic Fibrosis Center since 2002 and Director of the Eudowood Division of Pediatric Respiratory Sciences since 2019. Dr. Mogayzel’s research interests include the regulatory properties of the CFTR gene, mucociliary clearance and the development of new therapeutics for CF.
Dr. Mogayzel has published many journal articles and several book chapters on a variety of topics related to CF. Dr. Mogayzel is an ad hoc reviewer for several journals, including the Journal of Cystic Fibrosis and American Journal of Respiratory and Critical Care Medicine. He serves as chairman of the Clinical Practice Guidelines for Pulmonary Therapies Committee and the Therapeutic Development Network Protocol Review Committee, both of the Cystic Fibrosis Foundation. He is also a past chairman of the Cystic Fibrosis Foundation Center Committee that accredits cystic fibrosis centers in the US. He is currently on the Board of Directors of the Cystic Fibrosis Foundation.
J. Michael Collaco, MD, MS, MBA, MPH, PhD
Associate Professor of Pediatrics
Johns Hopkins University School of Medicine
Dr. J. Michael Collaco is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine. His clinical specialty is pediatric pulmonary medicine, including chronic lung disease of premature infants, lung disease in medically complex patients including ventilators and tracheostomies, hereditary hemorrhagic telangiectasia, aerodigestive disorders and general pediatric pulmonary conditions. Dr. Collaco’s primary research interest is in the epidemiology of pediatric respiratory diseases, with a focus on environmental risk factors for CF and bronchopulmonary dysplasia as well as a special interest in the effects of secondhand smoke and electronic cigarette emissions. He has published over 100 peer-reviewed articles.
Sarah Chart, RN
Rebecca Gleason, RN, CCM
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, OptumHealth Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
Dr. Mogayzel has received grant funding from Boehringer Ingelheim, Eloxx Pharmaceuticals and Vertex Pharmaceuticals.
The remaining activity faculty or planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, this activity has been planned and implemented by OptumHealth Education and UnitedHealthcare. OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.00 contact hour ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour.
Unique Activity Number(s): JA0007123-9999-21-165-H04-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hours for Certified Case Managers (CCM).
OptumHealth Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 1.00 CE hour.
As a Jointly Accredited Organization, OptumHealth Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. OptumHealth Education maintains responsibility for this course. Social workers completing this course receive 1.00 live continuing education credits.
Counselors and/or marriage and family therapists
CA: The Board of Behavioral Sciences has deferred CE course approvals to APA and ASWB for its licensees. See those approvals under Psychologists and Social Workers.
Other States: If your state is not specifically listed, nearly all state Counselor and MFT boards accept either APA or ASWB approval, or are reciprocal with other state licensing board approvals, such as those listed below. Check with your board to be sure.
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization from which they wish to obtain credit.
- 1.00 ACPE - Pharmacist
- 1.00 ACPE - Pharmacy Technician
- 1.00 AMA
- 1.00 ANCC
- 1.00 APA
- 1.00 Attendance
- 1.00 CCMC - General
You must be logged into your account to participate in this activity. Get started by clicking “Register” and completing the “Pre-Activity Assessment”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of your activities can be found under “My Account,” “My Activities.”